Patent Dispute Update: Incyte Blocks U.S. Launch of Sun Pharma’s Deuruxolitinib (Leqselvi) for Alopecia Areata
The Dermatology Digest
NOVEMBER 5, 2024
Incyte filed a lawsuit to try to block the launch of deuruxolitinib, claiming that it infringed on a patent on the use of ruxolitinib (Opzelura), which is approved for atopic dermatitis and vitiligo. Sun Pharma acquired deuruxolitinib when it purchased Concert Pharmaceuticals in March 2023 and received the U.S,
Let's personalize your content